#LaurusLabs Q3'25 Results
- Revenues 1,415cr +18% YoY, +16% QoQ
- EBITDA 285cr +56% YoY, +57% QoQ
- PAT 92cr +300% YoY, +360% QoQ
- CDMO business where revenues were up 89% YoY, up 34% QoQ driven by new asset ramp ups and clinical project advancements
- Formulations division where revenues were up 19% YoY and up 33% QoQ
- API division where revenues were down 7% YoY, down 5% YoY
- reconfirmed FY25 outlook

Other Highlights
- Laurus Labs along with Eight Roads Ventures (& F-Prime Capital) will invest 40cr and 120cr respectively in Laurus Labs' subsidiary Laurus Bio with respective ownership after the investment will be 75% and 14% respectively. Funds will be used to build a new large-scale commercial microbial fermentation facility with a capacity of over 400 KL in Vizag with expected completion to be end of 2026.